Abcellera Biologics Inc (ABCL) — Cash Flow Reinvestment Rate

Latest as of June 2023: 1.89x

Abcellera Biologics Inc (ABCL) has a Cash Flow Reinvestment Rate of 1.89x as of June 2023, reinvesting $37.52 Million (capex $27.35 Million plus investments $-10.17 Million) from operating cash flow of $19.82 Million. Explore Abcellera Biologics Inc (ABCL) reinvestment ratio to see what proportion of operating cash flow is directed to capital expenditures.

Reinvestment Rate

1.89x
(Capex + Investments) / Operating CF

Total Reinvested

$37.52 Million
Capex + Investments

Operating Cash Flow

$19.82 Million
USD

Capital Expenditures

$27.35 Million
USD

Abcellera Biologics Inc Cash Flow Reinvestment Rate (2018–2022)

Historical reinvestment intensity for Abcellera Biologics Inc across 5 annual periods. Also explore Abcellera Biologics Inc (ABCL) total assets for the complete picture of this company's asset base.

Annual Cash Flow Reinvestment Rate for Abcellera Biologics Inc (2018–2022)

Year-by-year capital reinvestment analysis for Abcellera Biologics Inc. For live market cap and broader valuation context, see market value of Abcellera Biologics Inc.

Year Reinvestment Rate Total Reinvested (USD) Operating CF Capex YoY Change
2022 1.53x $425.29 Million $277.36 Million $72.66 Million ▲ +11.7%
2021 1.37x $335.88 Million $244.58 Million $58.45 Million ▼ -8.1%
2020 1.49x $33.92 Million $22.69 Million $14.67 Million ▼ -58.8%
2019 3.63x $9.78 Million $2.69 Million $4.00 Million ▲ +21.9%
2018 2.98x $10.61 Million $3.56 Million $5.31 Million
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow